Clinical trials: GLP - 1
Type 2 Diabetes
A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186
This study will assess the safety, tolerability, and pharmacokinetics of AZD0186 following single ascending doses (SAD) via oral administration in healthy adult participants.
- Trial name
- NCT05694741
- Testing
- AZD0186
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes, Heart Failure
The Effects of Neprilysin on Glucagon-like Peptide-1
In the current study we wish to investigate the effects on glucagon-like peptide-1 (GLP-1) of a neprilysin inhibitor
- Trial name
- NEP (NCT03717688)
- Testing
- Entresto, Sitagliptin 100mg
- Where
- Denmark
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Postural Orthostatic Tachycardia Syndrome (POTS), Healthy
POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS
This study will describe the interplay between the gut hormones GIP and CCK and their regulation of blood flow to the large vessels in patients with Postural Orthostatic Tachycardia Syndrome (POTS) and GIP, CCK and GLP-1 in…
- Trial name
- GA22 (NCT07019519)
- Testing
- GIPR antagonist, GLP-1R antagonist, CCK agonist
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion
The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion
The last couple of years it has been shown that bile acids not only acts as simple emulsifiers of fat, but constitutes a complex metabolic integrator which not only have an influence on fat digestion and lipid metabolism, but…
- Trial name
- NCT01656057
- Testing
- Acetaminophen, Metformin, Colesevelam
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Filip Krag Knop
Pre-diabetes, Older Adults
Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.
The goal of this study is to evaluate the hypothesis that the addition of liraglutide, a long-acting glucagon-like peptide 1 (GLP-1) analogue, to a calorie-restricted diet will lead to greater weight loss than will a…
- Trial name
- NCT01784965
- Testing
- liraglutide
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Stanford University
Normal Healthy Volunteer, Safety After Oral Intake
A Research Study to Evaluate BLX-7006 in Healthy Adults
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection.
- Trial name
- NCT07140055
- Testing
- BLX-7006
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Obesity
Location of GLP-1 Release
Background: Physicians do not have a unified, scientifically tested theory of causation for obesity and its comorbidities, nor do they have explanations for the mechanics of the metabolic/bariatric surgery procedures.
- Trial name
- NCT02036710
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Vagotomy, Truncal
Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects
The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of glucose and Glucagon-like peptide-1 (GLP-1) in respect to insulin secretion.
- Trial name
- NCT01176760
- Testing
- Dipeptidyl peptidase 4 (DPP 4) inhibitor, oral glucose
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen